fingolimod has been researched along with mk-1775 in 1 studies
| Studies (fingolimod) | Trials (fingolimod) | Recent Studies (post-2010) (fingolimod) | Studies (mk-1775) | Trials (mk-1775) | Recent Studies (post-2010) (mk-1775) |
|---|---|---|---|---|---|
| 65 | 0 | 51 | 195 | 26 | 188 |
| Protein | Taxonomy | fingolimod (IC50) | mk-1775 (IC50) |
|---|---|---|---|
| Wee1-like protein kinase | Homo sapiens (human) | 0.023 | |
| Serine/threonine-protein kinase PLK1 | Homo sapiens (human) | 0.1825 | |
| Membrane-associated tyrosine- and threonine-specific cdc2-inhibitory kinase | Homo sapiens (human) | 3.14 | |
| Serine/threonine-protein kinase WNK3 | Homo sapiens (human) | 2.31 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Hadden, MK; Wen, J | 1 |
1 review(s) available for fingolimod and mk-1775
| Article | Year |
|---|---|
Medulloblastoma drugs in development: Current leads, trials and drawbacks.
Topics: Animals; Antineoplastic Agents; Cell Line, Tumor; Cerebellar Neoplasms; Humans; Medulloblastoma; Protein Kinase Inhibitors | 2021 |